We take UK medical device, diagnostics and pharmaceutical companies into six markets where a local representative is a legal precondition for registration — and where a UKCA mark, on its own, counts for nothing.
A route assessment takes two weeks and starts at £1,450. No retainer, no commitment.
We went deep on six rather than shallow on forty. Each has its own regulator, its own representative rule and its own trap.
The regulator expects your representative to confirm no other representative holds the same product group. Exclusivity is a structural decision, not a commercial one.
Since early 2026 the rules push in the opposite direction to Saudi Arabia: more than one agent per product. Selling into both needs two different structures.
The registration holder cannot be transferred. Choose the wrong partner and changing distributor means losing the market authorisation entirely.
The system is harmonised with the EU — but the customs-union route stopped applying to UK manufacturers after Brexit. A Turkish representative is mandatory.
A Certificate of Free Sale, trademark registration and sample analysis all sit on the critical path. Sequencing them wrongly adds months, not weeks.
The representative must be a natural person resident in South Africa — not a company. That single line changes how the whole engagement is structured.
Where these regulators shorten their review at all, the recognised lists were written around the FDA, the EU, Canada, Australia and Japan — and some have withdrawn the shortcut entirely. A UKCA mark appears on none of them. UK manufacturers who moved from CE to UKCA after Brexit are frequently worse off abroad than they were before.
| Market | Shortens review | UKCA alone |
|---|---|---|
| Saudi Arabia | Reliance route discontinued in 2020 — one dossier route for everyone | No shortcut |
| South Africa | Explicit reliance pathway, several regulators | Not listed |
| Türkiye | EU-harmonised system | Insufficient |
| UAE · Egypt · Nigeria | No formal reliance route | No effect |
Saudi Arabia verified against SFDA publications, August 2026. Every market page names its own sources and the date it was last checked.
In several of these markets the market authorisation is issued to a local entity and cannot be transferred. If that entity is your distributor, then your distributor owns your access to the market — and the commercial conversation changes permanently the day you want to replace them.
The alternative is independent representation: the licence sits with a partner whose only role is to hold it, and you keep the freedom to change who sells for you.
| Situation | Consequence |
|---|---|
| Registration held by your distributor | Changing distributor can mean re-registering from zero |
| Egypt — holder not transferable | No mechanism to move it at all |
| Independent representative | Distribution and registration stay separable |
Regulatory buyers check this first, so we put it on the front page rather than in the small print.
Two weeks. You get a written route per market: what applies, what is missing from your file, what it costs and how long it takes.
We shortlist and contract the local representative, with terms that keep the registration in your name and separable from distribution.
Dossier assembly, translation and legalisation, submission, and management of the regulator's questions until the authorisation issues.
Renewals, variations, added SKUs and post-market obligations — so the approval you paid for does not quietly lapse.
Government fees and representative licences are billed at cost and shown separately. Nothing here is a percentage of your revenue.
One product family, up to two markets. Written route, cost model and document gap list. Credited against the project if you proceed.
Per product family, per market. Includes representative appointment, dossier, submission and regulator correspondence. Official fees at cost.
Per market, per year. Renewals, variations, new SKUs, correspondence and a quarterly regulatory change note for your file.
No — and you should be careful with anyone in the UK who says they can. In all six markets the role must sit with a locally established person or entity. We appoint one, contract them properly and manage them. That separation is the point, not a limitation.
Possibly not — but ask them one question first: whose name will be on the registration. If it is theirs, you have handed them your market access along with your sales. That is fixable at the start and expensive to fix later.
It is not a barrier, but it is not an asset either. None of these regulators shortens its review on the strength of a UKCA mark alone. If you also hold CE or FDA clearance, several of them will move faster — and we will tell you which route is cheaper before you spend anything.
Every page carries the date it was last checked against the regulator's own publications, and we re-check quarterly. Where a rule is in flux — and several are — we say so on the page rather than quoting a number that has moved.
Tell us the product and the markets you are considering. Two weeks later you will have a written route, a cost model and an honest view of whether it is worth doing at all.
Check your routeOr reach us directly — mail@bcabusiness.co.uk · +44 7342 901002 · WhatsApp